News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Winston Laboratories, Inc. Receives Notice of Compliance in Canada for CIVANEX(TM) (Civamide Cream) for Treatment of Osteoarthritis


7/20/2010 10:18:48 AM

VERNON HILLS, Ill.--(BUSINESS WIRE)--Winston Laboratories, Inc., a wholly-owned subsidiary of Winston Pharmaceuticals, Inc. (“Winston”) (OTC PINK: WPHM), a pharmaceutical company focused on developing and commercializing novel pain management therapies, announced that it has received Notice of Compliance (NOC) from the Therapeutics Drug Directorate, Health Canada for its New Drug Submission (NDS) for CIVANEX ™ (zucapsaicin cream 0.075%) for the treatment of the signs and symptoms of osteoarthritis.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES